Brought to you by 
Leo Pharma gains rights to two dermatology mAbs from AstraZeneca
16 Aug 2019
Executive Summary
Leo Pharma AS strengthened its dermatology offerings and entered the biologics space through the licensing of AstraZeneca PLC's tralokinumab and brodalumab, two monoclonal antibodies for skin diseases and plaque psoriasis, respectively.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Leo Pharma gains rights to two dermatology mAbs from AstraZeneca
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice